icon-folder.gif   Conference Reports for NATAP  
 
  15th European AIDS Conference (EACS)
October 21-24, 2015
Barcelona
Back grey_arrow_rt.gif
 
 
 
Second-generation HIV-1 Maturation Inhibitor BMS-955176: Overall Antiviral Activity and Safety Results from the Phase IIa Proof-of-Concept Study (AI468002)
 
 
  Reported by Jules Levin
EACS 2015 Oct 20-24 Barcelona, Spain - 15th European AIDS Conference
 
Carey Hwang,1 Dirk SchŘrmann,2 Christian Sobotha,2 Marta Boffito,3 Heather Sevinsky,1 Neelanjana Ray,1 Palanikumar Ravindran,1 Hong Xiao,1 Mark Krystal,4 Ira Dicker,4 Dennis Grasela,1 and Max Lataillade,4 on behalf of the BMS HIV Global Development Team
1Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA 2CharitÚ Research Organisation GmbH, CharitÚplatz 1, 10117 Berlin, Germany 3St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK 4Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA

EACS1.gif

EACS2.gif

EACS3.gif

EACS4.gif

EACS5.gif

EACS6.gif

EACS7.gif

EACS8.gif

EACS9.gif

EACS10.gif

EACS11.gif

EACS12.gif

EACS13.gif

EACS14.gif

EACS15.gif

EACS16.gif

EACS17.gif

EACS18.gif

EACS19.gif

EACS20.gif

EACS21.gif

EACS22.gif